Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 701–800 of 1,000
Trask-Marino, A. L., Marino, B., Lancefield, T. F., See, E. J., May, C. N., Booth, L. C., Raman, J., & Lankadeva, Y. R. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2024 · Cited by 22
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3440 · Cited by 24
Self-citationVlasopoulou, K., Synetos, A. G., Ktenopoulos, N., Katsaros, O., Koliastasis, L., Apostolos, A., Drakopoulou, M. I., Toutouzas, K. P., & Tsioufis, K. P. (2025) · Medical Sciences · doi:10.3390/medsci13030204 · Cited by 20
“…trials (RCTs) with angiotensin-converting enzyme inhibitors (ACE-Is) [117–119], angiotensin receptor blockers (ARBs) [118,119], mineralocorticoid receptor antagonists (MRAs) [116], and angiotensin receptor–neprilysin inhibitors (ARNIs) [120,121] have failed to meet their primary end-points.”
Anker, S. D., Khan, M. S., Shahid, I., Filippatos, G. S., Coats, A. J. S., & Butler, J. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2279 · Cited by 22
Gavina, C., Seabra, D., Dias, D. M., Bernardo, F., Martinho, H. M., Couceiro, J., Santos-Araújo, C., Dinis‐Oliveira, R. J., & Taveira‐Gomes, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082131 · Cited by 21
“i sis s s l r t r r i r i r t rs t f i ti it i i l t i t t t i l i : ARAGON-HF [14] and DAPA-HF [15].”
BackgroundMethodInfluentialKšela, J., Rupert, L., Djordjević, A., Antonič, M., Avbelj, V., & Jug, B. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070213 · Cited by 20
He, Q., Chen, B., Wang, G., Zhou, D., Zeng, H., Li, X., Song, Y., Yu, X., Liang, W., Chen, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842879 · Cited by 20
“Several pharmaceutical co-crystal formulations have been developed to treat cardiovascular and metabolic diseases, such as entresto for heart failure (Solomon et al., 2019), pasiniazid as antituberculosis (Zhang Y.”
BackgroundFu, M. L. X., Pivodic, A., Käck, O., Costa‐Scharplatz, M., Dahlström, U., & Lund, L. H. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02124-w · Cited by 19
“1 3 in HF-related hospitalizations and CV-related death with ARNI versus angiotensin 2 receptor blocker (ARB) in a prespecified patient population with LVEF ≤ 57% [2].”
BackgroundPrevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
Curtain, J. P., Adamson, C., Docherty, K. F., Jhund, P. S., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Swedberg, K. B., Zile, M. R., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.12.012 · Cited by 19
Self-citationKautzky‐Willer, A., Leutner, M., Abrahamian, H., Frühwald, L., Hoppichler, F., Lechleitner, M., & Harreiter, J. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02185-5 · Cited by 24
Ding, J., Cui, S., Li, S. Y., Cui, L. Y., Nan, Q. Y., Lin, X. J., Xuan, M. Y., Jin, J., Piao, S. G., Jiang, Y. J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286903 · Cited by 19
RetractedNew Therapeutics for Heart Failure: Focusing on cGMP Signaling
Mangmool, S., Duangrat, R., Parichatikanond, W., & Kurose, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612866 · Cited by 21
“These findings raise concerns regarding the potential side effects of LCZ696 in HFpEF patients [114].”
BackgroundInfluentialHabel, N., Infeld, M. M., Bernknopf, J., Meyer, M., & Lustgarten, D. L. (2023) · Heart Rhythm O2 · doi:10.1016/j.hroo.2023.12.001 · Cited by 20
Minamisawa, M., Inciardi, R. M., Claggett, B. L., Čikeš, M., Liu, L., Prasad, N., Biering‐Sørensen, T., Lam, C. S. P., Shah, S. J., Zile, M. R., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3167 · Cited by 20
Self-citationEpidemiology and Risk Factors for Hyperkalaemia in Heart Failure
Grobbee, D. E., Filippatos, G. S., Desai, N. R., Coats, A. J. S., Pinto, F. J., Rosano, G. M. C., Cleland, J. G. F., Kammerer, J. A., & de Arellano, A. R. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14661 · Cited by 20
Self-citationHiraiwa, H., Okumura, T., & Murohara, T. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00641-9 · Cited by 23
“Among the medical treatments described in this review, the PARAGON-HF study demonstrated the influence of sex differences on the treatment outcomes [88], but this is an area set for further development.”
BackgroundInfluentialBae, J. P., Kallenbach, L., Nelson, D. R., Lavelle, K., Winer-Jones, J. P., Bonafede, M., & Murakami, M. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01589-2 · Cited by 22
Yang, M., Kondo, T., Talebi, A., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3263 · Cited by 20
Self-citationPatel-Murray, N. L., Zhang, L., Claggett, B. L., Xu, D., Serrano‐Fernández, P., Healey, M. L., Wandel, S., Chen, C., Jacob, J., Xu, H., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033544 · Cited by 22
Self-citationSolano, S., Yang, M., Tolomeo, P., Kondo, T., Shen, L., Jhund, P. S., Anand, I. S., Desai, A. S., Lam, C. S. P., Maggioni, A. P., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037782 · Cited by 19
Self-citationManagement of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy
Butler, J., Januzzi, J. L., & Rosenstock, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14042 · Cited by 20
“Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) study compared sacubitril/valsartan and valsartan in patients with HF (NYHA class II-IV) and preserved EF (defined as ≥45%).(54) The primary composite outcome of total HHF (first and recurrent) and cardiovascular death was observed in…”
ResultSex differences in circulating proteins in heart failure with preserved ejection fraction
Stienen, S., Ferreira, J. P., Kobayashi, M., Preud’homme, G., Dobre, D., Machu, J., Duarte, K., Bresso, E., Devignes, M., López‐Andrés, N., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00322-7 · Cited by 21
Self-citationCardiac fibrosis: emerging agents in preclinical and clinical development
Spoladore, R., Falasconi, G., Fiore, G., Maio, S. D., Preda, A., Slavich, M., Margonato, A., & Fragasso, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868432 · Cited by 21
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
Cho, I., & Kang, S. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.900 · Cited by 20
“In contrast to the promising results from patients with HFrEF, the Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial in patients with HFpEF showed that sacubitril/valsartan did not result in a significantly lower rate of total HF hospitalizations and card…”
ResultKidney function assessment and endpoint ascertainment in clinical trials
Khan, M. S., Bakris, G. L., Packer, M., Shahid, I., Anker, S. D., Fonarow, G. C., Wanner, C., Weir, M. R., Zannad, F. M., & Butler, J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab832 · Cited by 19
Self-citationRisk of heart failure with preserved versus reduced ejection fraction in women with breast cancer
Kwan, M. L., Cheng, R. K.-H., Iribarren, C., Shen, H., Laurent, C. A., Roh, J. M., Hershman, D. L., Kushi, L. H., Greenlee, H., & Rana, J. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06586-4 · Cited by 19
“For the present analysis, we selected LVEF status for HFpEF (LVEF ≥ 45%) and HFrEF (LVEF < 45%) based on prior major clinical trials testing the efficacy of emerging therapies for HFpEF [7, 8].”
MethodIchiki, T., Jinno, A., & Tsuji, Y. (2022) · Biology · doi:10.3390/biology11060859 · Cited by 19
“reported that sacubitril/valsartan did not improve the risk of death and rehospitalization in patients with preserved EF from the phase III PARAGON-HF trial [66].”
BackgroundBreakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
Talha, K. M., & Butler, J. (2022) · Clinical Cardiology · doi:10.1002/clc.23846 · Cited by 19
Chung, Y. J., Choi, K. H., Lee, S. H., Shin, D., Hong, D., Park, S., Joh, H. S., Kim, H. K., Ha, S. J., Park, T. K., et al. (2022) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2022.11.014 · Cited by 19
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 22
Matsumoto, S., Nakazawa, G., Ohno, Y., Ishihara, M., Sakai, K., Nakamura, N., Murakami, T., Natsumeda, M., Kabuki, T., Shibata, A., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13042 · Cited by 19
Bozkurt, B., & Ezekowitz, J. A. (2020) · Circulation · doi:10.1161/circulationaha.120.045008 · Cited by 19
Schiattarella, G. G., Tong, D., & Hill, J. A. (2020) · Circulation · doi:10.1161/circulationaha.119.045171 · Cited by 19
Okuno, T., Kagami, K., Harada, T., Hoshiga, M., Ishii, H., & Obokata, M. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0214 · Cited by 20
Lee, V., Dalakoti, M., Zheng, Q., Toh, D., Boubertakh, R., Bryant, J., Aw, T. C., Lee, C., Richards, M., Butler, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62203-0 · Cited by 19
“…of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) reported that sacu-bitril/valsartan did not result in signi fi cantly lower rates of HF hospitalizations and cardiovascular deaths in patients with HF and preserved ejection fraction (HFpEF) compared to valsartan 20 .”
Self-citationLi, Z., LaPenna, K. B., Gehred, N., Yu, X., Tang, W. H. W., Doiron, J. E., Xia, H., Chen, J., Driver, I. H., Sachse, F. B., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.326042 · Cited by 18
Self-citationVaduganathan, M., Claggett, B. L., Chatur, S., Desai, A. S., Jhund, P. S., Vardeny, O., Merkely, B. P., Martínez, F. A., Colet, J. C., Saraiva, J. F. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04037-3 · Cited by 20
“The ARNI sacubitril/ valsartan, which targets both the renin–angiotensin system and the natriuretic peptide axis, appears to be most beneficial in those with LVEF below normal 5,6 and is now approved for use in many countries worldwide for this indication.”
InfluentialSelf-citationThe E/e’ Ratio—Role in Risk Stratification of Acute Heart Failure with Preserved Ejection Fraction
Zamfirescu, M.-B., Ghilencea, L.-N., Popescu, M. R., Bejan, G. C., Maher, S. M., Popescu, A.-C., & Dorobanţu, M. (2021) · Medicina · doi:10.3390/medicina57040375 · Cited by 19
Management of Pulmonary Hypertension in Left Heart Disease
Macera, F., & Vachiéry, J. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/rkqn5397 · Cited by 18
“38 HFpEF (LVEF ≥ 45%) NYHA II-IV PH (mPAP > 25, PAWP > 15 mm Hg) Sildenafil (26) vs placebo (26) for 12 weeks Echocardiographic parameters (RV/LV dimensions and function) CPET, QoL No significant differences”
BackgroundSodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: An Updated Meta-Analysis
Cao, Y., Li, P., Li, Y., & Han, Y. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13905 · Cited by 22
“It should be noted that the therapeutic effect is different between HFpEF patients with LVEF > 60% and HFrEF patients, which has been demonstrated by the results of PARAGON-HF study and EMPEROR-Preserved study.(18,31) This may be partly due to the apparently lower incidence of cardiovascular events (e.”
ResultFunamoto, M., Sunagawa, Y., Katanasaka, Y., Kato, T., Funada, J., Ajiro, Y., Komiyama, M., Akao, M., Yasoda, A., Yamakage, H., et al. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac057 · Cited by 18
Update on Atrial Shunt Therapy for Treatment of Heart Failure
Litwin, S. E., Borlaug, B. A., Komtebedde, J., & Shah, S. J. (2022) · Structural Heart · doi:10.1016/j.shj.2022.100090 · Cited by 19
Self-citationQin, J., Wang, W., Wei, P., Huang, P. C., Lin, R., & Yue, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.982372 · Cited by 18
Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation
Țica, O., Khamboo, W., & Kotecha, D. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.03 · Cited by 20
Farajidavar, N., O’Gallagher, K., Bean, D. M., Nabeebaccus, A., Zakeri, R., Bromage, D. I., Kraljević, Ž., Teo, J., Dobson, R., & Shah, A. M. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-03005-w · Cited by 19
“Unlike HF with reduced Ejection 53 Fraction (HFrEF), no evidence-based therapies are available for HFpEF[11-13].”
BackgroundPolypharmacy in Older People with Heart Failure: Roles of the Geriatrician and Pharmacist
Stefil, M., Dixon, M. R., Bahar, J., Saied, S., Mashida, K., Heron, O., Shantsila, E., Walker, L. E., Akpan, A., Lip, G. Y. H., et al. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.14 · Cited by 19
Wang, X., Jering, K., Čikeš, M., Tokmakova, M. P., Mehran, R., Han, Y., East, C. A., Mody, F. V., Wang, Y., Lewis, E. F., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028942 · Cited by 18
Self-citationBalligand, J., Brito, D. A., Brosteanu, O., Casadei, B., Depoix, C. L., Edelmann, F., Ferreira, V. M., Filippatos, G. S., Gerber, B. L., Gruson, D., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3003 · Cited by 19
Self-citationThe Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF
Triposkiadis, F. K., Briasoulis, Α., Sarafidis, P. A., Magouliotis, D. E., Athanasiou, T., PARASKEVAIDIS, I. A., Skoularigis, J. S., & Xanthopoulos, A. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206486 · Cited by 20
Endpoint adjudication in cardiovascular clinical trials
Khan, M. S., Usman, M., Spall, H. G. C. V., Greene, S. J., Baqal, O. J., Felker, G. M., Bhatt, D. L., Januzzi, J. L., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad718 · Cited by 19
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
Mann, D. L., Nicolas, J., Claggett, B. L., Miao, Z. M., Granger, C. B., Kerkar, P. G., Køber, L., Lewis, E. F., McMurray, J. J. V., Maggioni, A. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.002 · Cited by 20
Self-citationSchupp, T., Bertsch, T., Reinhardt, M., Abel, N., Schmitt, A., Lau, F., Abumayyaleh, M., Akin, M., Weiß, C., Weidner, K., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae121 · Cited by 19
An analysis of multidrug multicomponent crystals as tools for drug development
Kavanagh, O. N. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.034 · Cited by 18
Kondo, T., Jhund, P. S., Anand, I. S., Claggett, B. L., Desai, A. S., Docherty, K. F., Lam, C. S. P., Lefkowitz, M. P., Maggioni, A. P., Martínez, F. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.12.010 · Cited by 18
Self-citationHsu, Y.-L., Lee, C., Chung, W., Lee, W.-H., Lee, K., Tsai, J.-H., Hsu, H., Yang, S., Loh, Z.-J., Su, P., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3758 · Cited by 18
Huusko, J., Purmonen, T. T., Toppila, I., Lassenius, M. I., & Ukkonen, H. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12665 · Cited by 18
Bilak, J. M., Gulsin, G. S., & McCann, G. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980235 · Cited by 21
Heart failure following transcatheter aortic valve replacement
Panagides, V., Alperi, A., Mesnier, J., Philippon, F., Bernier, M., & Rodés‐Cabau, J. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1949987 · Cited by 21
“benefits in mid-range EF patients [136].”
Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure
Gidlöf, O. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.650124 · Cited by 19
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure
Ferreira, J. P., Packer, M., Butler, J., & Zannad, F. M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2457 · Cited by 19
Self-citationNewer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage
Upadhya, B., Kozak, P. M., Stacey, R. B., & Vasan, R. S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01166-9 · Cited by 19
Mechanical circulatory support devices and treatment strategies for right heart failure
Kuroda, T., Miyagi, C., Fukamachi, K., & Karimov, J. H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.951234 · Cited by 18
Chen, H. H., Tesic, M. B., Nikolic, V. N., Pavlović, M., Vučić, R. M., Spasić, A., Jovanović, H., Jovanović, I., Town, S. E. L., Padula, M. P., et al. (2022) · Biomolecules · doi:10.3390/biom12101419 · Cited by 19
“To date, no drugs have shown effectiveness in the management of patients with chronic HFpEF and prevention of acute HFpEF, which is likely due to the poorly understood pathogenesis of HFpEF [3].”
BackgroundChoi, K. H., Yang, J. H., Seo, J., Hong, D., Youn, T., Joh, H. S., Lee, S. H., Kim, D., Park, T. K., Lee, J. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027581 · Cited by 18
“…targeted therapy for HFpEF, the currently available evidence is inadequate to support specific drug regimens for patients who present with HFpEF, 2– 7 probably because the fundamental pathophysiology of HFpEF is poorly understood, and a firm diagnosis of HFpEF remains a challenge in real-world…”
Khandait, H. V., Sodhi, S. S., Khandekar, N., & Bhattad, V. B. (2025) · Cardiorenal Medicine · doi:10.1159/000542633 · Cited by 20
“In the two large trials, PARAGON HF [12] and EMPEROR Preserved [13], 47% and 50% cases, respectively, had an eGFR of 60 mL/min/1.73 m 2 .”
InfluentialBaris, R. O., & Tabit, C. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165894 · Cited by 21
“In light of the available literature and clinical data, sacubitril/valsartan (ARNI) therapy appears to be superior to other treatment modalities [17,38].”
Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
Spitaleri, G., Lupón, J., Domingo, M., Santiago‐Vacas, E., Codina, P., Zamora, E., Cediel, G., Santesmases, J., Díez, C., Troya, M. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79926-3 · Cited by 20
Gallo, G., Volpe, M., Battistoni, A., Russo, D., Tocci, G., & Musumeci, B. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.652163 · Cited by 18
“Regarding the secondary endpoints, a significant improvement of functional status (NYHA class) and of quality of life (Kansas City Cardiomyopathy Questionnaire) was shown in patients treated with S/V compared to valsartan alone (Solomon et al., 2019).”
BackgroundMethodResultInfluentialPrognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure
Jang, S. Y., & Yang, D. H. (2022) · International Journal of Heart Failure · doi:10.36628/ijhf.2021.0039 · Cited by 18
From mid-range to mildly reduced ejection fraction heart failure: A call to treat
Stolfo, D., Fabris, E., Lund, L. H., Savarese, G., & Sinagra, G. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.05.030 · Cited by 18
Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF)
Schulz, L., Werner, S., Böttner, J., Adams, V., Lurz, P. C., Besler, C., Thiele, H., & Buttner, P. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-19766-5 · Cited by 17
The Cardiovascular Effects of SGLT2 Inhibitors, RAS Inhibitors, and ARN Inhibitors in Heart Failure
Ji, P., Zhang, Z., Yan, Q., Cao, H., Zhao, Y., Yang, B., & Li, J. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14298 · Cited by 18
Zhang, T., Wang, X., Wang, Z., Zhai, J., He, L., Wang, Y., Zuo, Q., Ma, S., Zhang, G., & Guo, Y. (2023) · Pharmacology · doi:10.1159/000533277 · Cited by 17
Fudim, M., Litwin, S. E., Borlaug, B. A., Mohan, R. C., Price, M. J., Fail, P. S., Zirakashvili, T., Shaburishvili, T., Goyal, P., Hummel, S. L., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.12.010 · Cited by 18
Self-citationThe recent advance and prospect of natural source compounds for the treatment of heart failure
Chen, X.-J., Liu, S., Li, S., Feng, J.-K., Hu, Y. C., Cheng, X., Hou, C., Xu, Y., Hu, M., Ling, F., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27110 · Cited by 20
“Moreover, ARNIs can be used to treat patients who are resistant to ACEIs or ARBs and is expected to become a cornerstone drug in the treatment of chronic HF [85].”
BackgroundHeart failure with preserved ejection fraction: The role of inflammation
Liu, H., Magaye, R., Kaye, D. M., & Wang, B. H. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176858 · Cited by 21
Butt, J. H., McMurray, J. J. V., Claggett, B. L., Jhund, P. S., Neuen, B. L., McCausland, F. R., Desai, A. S., Lam, C. S. P., Pitt, B., Pfeffer, M. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071110 · Cited by 17
Self-citationClinical Update in Heart Failure with Preserved Ejection Fraction
Krittanawong, C., Britt, W., Rizwan, A. M., Siddiqui, R., Khawaja, M., Khan, R., Joolharzadeh, P., Newman, N. A., Rivera, M. R. R., & Tang, W. H. W. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00679-5 · Cited by 20
“…with ARB [angiotensin-receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial, sacubitril/valsartan did not reduce the composite endpoint of cardiovascular death or total HF hospitalizations in patients with HF with LVEF ≥ 45% compared to valsartan [118].”
Causland, F. R. M., Vaduganathan, M., Claggett, B. L., Gori, M., Jhund, P. S., McGrath, M. M., Neuen, B. L., Packer, M., Pfeffer, M. A., Rouleau, J. L., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.022 · Cited by 18
Self-citationChinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
Chinese Society of Cardiology, C. M. A., Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, & Editorial Board of Chinese Journal of Cardiology (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000146 · Cited by 50
Soluble ST2 and Soluble Markers of Fibrosis: Emerging Roles for Prognosis and Guiding Therapy
Sharim, J., & Daniels, L. B. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01288-z · Cited by 17
Yoshida, Y., Nakanishi, K., Daimon, M., Ishiwata, J., Sawada, N., Hirokawa, M., Kaneko, H., Nakao, T., Mizuno, Y., Morita, H., et al. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa156 · Cited by 17
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
Cuthbert, J. J., Pellicori, P., & Clark, A. L. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s234772 · Cited by 18
Besler, C., Rommel, K., Kresoja, K., Mörbitz, J., Kirsten, H., Scholz, M. R., Klingel, K., Thiery, J., Burkhardt, R., Buttner, P. G., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13327 · Cited by 17
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Oh, J., Lee, S., Lee, C. J., & Kang, S. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0070 · Cited by 19
New Targets in Heart Failure Drug Therapy
Correale, M., Tricarico, L., Fortunato, M., Mazzeo, P., Nodari, S., Biase, M. D., & Brunetti, N. D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.665797 · Cited by 17
“However, sacubitril/valsartan, in a recent phase III clinical research trial in patients with HFpEF, showed just a marginal reduction of the primary composite endpoint of total hospitalizations for HF and death from CV origin (40).”
BackgroundMiyagi, C., Kuban, B. D., Flick, C. R., Polakowski, A. R., Miyamoto, T., Karimov, J. H., Starling, R. C., & Fukamachi, K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10117-6 · Cited by 17
Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)
Eadie, A. L., Brunt, K. R., & Herder, M. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.794 · Cited by 20
Lebek, S., Hegner, P., Tafelmeier, M., Rupprecht, L., Schmid, Ç., Maier, L. S., Arzt, M. E., & Wagner, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.675987 · Cited by 17
“Most recently, in the PARAGON-HF trial, angiotensin receptor–neprilysin inhibitor sacubitril-valsartan was tested in patients with HFpEF, but treatment failed to reduce the combined endpoint of HF hospitalization and death from cardiovascular causes (17).”
BackgroundNew Antidiabetes Medications and Their Cardiovascular and Renal Benefits
Ferro, E. G., Elshazly, M. B., & Bhatt, D. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.007 · Cited by 21
Burgdorf, C., Brockmöller, J., Strampe, H., Januszewski, M., & Remppis, B. A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.734697 · Cited by 17
“Only recently, the PARAGONHF trial failed to unveil a significant benefit of angiotensin receptor-neprilysin inhibition with Sacubitril/Valsartan in HFpEF patients with respect to its primary composite outcome of total hospitalization for heart failure and death from cardiovascular causes (2).”
BackgroundBasile, C., Paolillo, S., Gargiulo, P., Marzano, F., Asile, G., Parlati, A. L. M., Chirico, A., Nardi, E., Buonocore, D., Colella, A., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001411 · Cited by 17
Mohammed, A., Abdu, F. A., Su, Y., Liu, L., Yin, G., Feng, Y., Zhang, W., Xu, Y., Xu, D., & Che, W. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.011 · Cited by 20
Heart failure with preserved ejection fraction: insights from recent clinical researches
Kim, M., & Park, S. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.104 · Cited by 18
“[68] reported the results of a pooled analysis of combined data from the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) [69] and PARAGON-HF [66] trials.”
BackgroundMethodInfluentialJackson, A. M., Jhund, P. S., Solomon, S. D., & McMurray, J. J. V. (2020) · Circulation · doi:10.1161/circulationaha.120.047275 · Cited by 17
Self-citationHeart failure and obesity: novel insights leading to new treatment paradigms
Meems, L. M. G., van Veldhuisen, D. J., Sattar, N. A., & Lee, M. M. Y. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01190-7 · Cited by 20
Kaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 19
One Syndrome, Many Faces: A Unified Perspective on Heart Failure Phenotypes
PARASKEVAIDIS, I. A., Tsougos, E., & Kourek, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188960 · Cited by 18
“Interestingly, therapeutic outcomes differ between patients with EF 57% and those above that threshold, suggesting the current cut-off may not be optimal [13].”
Kittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 25
Zhou, H., Zhan, R., Chen, X., Lin, Y.-F., Zhang, S., Zheng, H., Wang, X., Huang, M.-T., Xu, C., Liao, X., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14068 · Cited by 18
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.